SYNAGEVA BIOPHARMA CORP.

AES

Scientific research and development services of products and processes for the expression, screening, production and purification of proteins and other pharmaceutical compounds for research and industry; scientific development and optimization services in the nature of expression, evolution, screening, production and purification of proteins and other pharmaceutical compounds for production and expression processes of proteins and other pharmaceutical compounds;

DEDICATED TO RARE DISEASES

house mark for a full line of pharmaceuticals and pharmaceutical preparations;RARE DISEASES;

DEDICATED TO THE NEXT GENERATION

contract manufacturing in the field of pharmaceuticals and biopharmaceuticals;biologic and chemical compounds being a component in pharmaceutical preparations for rare, terminal and genetic diseases;biologic and chemical compounds for use in the manufacture of pharmaceutical preparations;patent licensing; licensing intellectual property;biological, pharmaceutical and medical research; medical and scientific research, namely, conducting clinical research; laboratory research services relating to pharmaceuticals; pharmaceutical drug development services; pharmaceutical research and development; scientific and technological services, namely, biological research and analysis; research and research services in the field of the transfer of biological molecules into living cells, integration of foreign nucleic acids into the genome of living cells and transient expression of proteins; development and research of new products for others; product development for others; platform technology, namely, protein expression platform for research and development of pharmaceuticals; platform technology, namely, protein expression platform for manufacturing protein-based therapeutics;

DRIVERS NEEDED

employment hiring, recruiting, staffing and career networking services; providing a web site featuring employment opportunities; providing employment information in the field of research, development, commercialization and distribution of pharmaceuticals and therapeutics; providing employment information in the field of rare, terminal and genetic diseases research, prevention, treatments, and patient care services; providing on-line employment information in the field of research, development, commercialization and distribution of pharmaceuticals and therapeutics; providing on-line employment information in the field of rare, terminal and genetic diseases research, prevention, treatments, and patient care services;providing information on rare, terminal and genetic diseases research, prevention, treatments, and patient care services; providing information on Lysosomal Acid Lipase Deficiency, research, prevention, treatments, and patient care services; providing information on research, design, commercialization and distribution of pharmaceuticals and therapeutics; providing a web site featuring information on rare, terminal and genetic diseases research, prevention, treatments, and patient care services; providing a web site featuring information on Lysosomal Acid Lipase Deficiency, research, prevention, treatments, and patient care services; providing a web site featuring information on research, development, commercialization and distribution of pharmaceuticals and therapeutics;scientific research and development concerning products and processes for the expression, evolution, screening, production and purification of proteins and other pharmaceutical compounds for research and industry; biological, pharmaceutical and medical research; medical and scientific research, namely, conducting clinical research; laboratory research services relating to pharmaceuticals; pharmaceutical drug development services; pharmaceutical research and development; scientific and technological services, namely, biological research and analysis; research and research services in the field of the transfer of biological molecules into living cells, integration of foreign nucleic acids into the genome of living cells and transient expression of proteins; development and research of new products for others;

GENN BIOLOGICS

pharmaceuticals and biologics for treatment of rare, terminal and/or genetic diseases; pharmaceuticals and biologics for protein replacement therapies;BIOLOGICS;

GENN BIOLOGICS

contract manufacturing in the field of pharmaceuticals and biopharmaceuticals;biologic and chemical compounds being a component in pharmaceutical preparations for rare, terminal and genetic diseases;biologic and chemical compounds for use in the manufacture of pharmaceutical preparations;patent licensing; licensing intellectual property;BIOLOGICS;biological, pharmaceutical and medical research; medical and scientific research, namely, conducting clinical research; laboratory research services relating to pharmaceuticals; pharmaceutical drug development services; pharmaceutical research and development; scientific and technological services, namely, biological research and analysis; research and research services in the field of the transfer of biological molecules into living cells, integration of foreign nucleic acids into the genome of living cells and transient expression of proteins; development and research of new products for others; product development for others; platform technology, namely, protein expression platform for research and development of pharmaceuticals; platform technology, namely, protein expression platform for manufacturing protein-based therapeutics;

GEVACARE

providing information to health care providers and patients in the fields of health insurance and other sources of funding for health care, and in the field of reimbursement of health care costs;providing health information; medical information;

KANALAL

pharmaceutical preparations for the treatment of enzyme deficiencies; pharmaceutical preparations for the treatment of lysosomal storage diseases; pharmaceutical preparations for the treatment of Liposomal Acid Lipase (LAL) deficiency;

KANLAL

pharmaceutical preparations for the treatment of enzyme deficiencies; pharmaceutical preparations for the treatment of lysosomal storage diseases; pharmaceutical preparations for the treatment of Liposomal Acid Lipase (LAL) deficiency;

KANLUMA

Pharmaceutical preparations for the treatment of enzyme deficiencies; pharmaceutical preparations for the treatment of lysosomal storage diseases; pharmaceutical preparations for the treatment of Lysosmal Acid Lipase (LAL) deficiency;

KANULAL

pharmaceutical preparations for the treatment of enzyme deficiencies; pharmaceutical preparations for the treatment of lysosomal storage diseases; pharmaceutical preparations for the treatment of Liposomal Acid Lipase (LAL) deficiency;

LOOK FOR LAL D!

education services, namely, conducting classes, conferences, lectures, seminars, workshops, and continuing medical education courses, in person, via the internet, or via webinar, in the field of medicine and healthcare; education services, namely conducting classes, conferences, lectures, seminars, workshops, and continuing medical education courses and workshops for medical professionals, in person, via the internet, or via webinar, in the field of Lysosomal Acid Lipase deficiency; electronic publications, namely books, newsletters, brochures, booklets, journal articles, academic publications, case studies, posters, educational course materials and handouts, reference guides, and teaching materials in the field of Lysosomal Acid Lipase deficiency;pharmaceuticals and pharmaceutical preparations for rare, terminal and genetic diseases; pharmaceuticals and pharmaceutical preparations for dyslipidemia, hepatic steatosis, liver disease, adrenal enlargement, adrenal calcification, growth retardation, and hepatic fibrosis; pharmaceuticals and pharmaceutical preparations for the treatment of enzyme deficiencies; pharmaceuticals and pharmaceutical preparations for the treatment of lysosomal storage diseases; pharmaceuticals and pharmaceutical preparations for the treatment of Liposomal Acid Lipase deficiency;printed matter, namely books, newsletters, brochures, booklets, journal articles, academic publications, case studies, posters, educational course materials and handouts, reference guides, and teaching materials in the field of Lysosomal Acid Lipase deficiency;promoting public awareness of Lysosomal Acid Lipase deficiency; providing information on Lysosomal Acid Lipase deficiency, research, prevention, treatments, and patient care services; providing information on rare, terminal and genetic diseases research, prevention, treatments, and patient care services; providing a web site featuring information on Lysosomal Acid Lipase deficiency, research, prevention, treatments, and patient care services; providing a web site featuring information on rare, terminal and genetic diseases research, prevention, treatments, and patient care services; providing a website featuring information regarding events promoting public awareness of Lysosomal Acid Lipase deficiency; providing information regarding medical treatment of diseases; providing information regarding medical treatment of Lysosomal Acid Lipase deficiency; providing support services for patients and families of patients with Lysosomal Acid Lipase Deficiency, namely, companionship, help with medical forms, help with insurance claims and forms, emotional counseling and emotional support;

SEP

Scientific research and development concerning products and processes for the expression, evolution, screening, production and purification of proteins and other pharmaceutical compounds for research and industry;

SYNAGEVA

Pharmaceutical preparations for the treatment of cancer, infectious diseases, organ dysfunction, genetic disorders, autoimmune diseases, cardiovascular diseases, neurological disorders, neurodegenerative disorders, blood disorders, infertility, gastrointestinal disorders, diseases of metabolism and organ diseases;

SYNAGEVA BIOPHARMA

house mark for a full line of pharmaceuticals and pharmaceutical preparations;SYNAGEVA BIO PHARMA;BIOPHARMA;

SYNAGEVA BIOPHARMA

Pharmaceutical preparations for rare, terminal, liver and genetic diseases and dyslipidemia;BIOPHARMA;

THE PEOPLE. THEIR LIVES. THE IMPACT.

pharmaceuticals and pharmaceutical preparations for rare, terminal and genetic diseases;providing information regarding medical treatment of diseases; providing information on rare, terminal and genetic diseases research, prevention, treatments, and patient care services; providing a web site featuring information on rare, terminal and genetic diseases research, prevention, treatments, and patient care services;scientific research and development concerning products and processes for the expression, evolution, screening, production and purification of proteins and other pharmaceutical compounds for research and industry;

ÜBERMAB

pharmaceutical preparations for use in ex vivo and in vivo treatment of cancer, inflammation and infectious diseases;